Congo trial of Ebola treatments switches to focus on two drugs

By | August 12, 2019

LONDON (Reuters) – A clinical trial of four potential Ebola treatments in Congo has been narrowed to focus on two of the experimental drugs – Regeneron’s REGN-EB3 and a monoclonal antibody called mAb114 – after they showed encouraging results, scientists leading the trial said on Monday.

Two other experimental treatments – ZMapp, an intravenous treatment made by Mapp Biopharmaceutical and Remdesivir, made by Gilead Sciences, will now be dropped from the trial, the researchers said.

Reporting by Kate Kelland, editing by Deepa Babington

Reuters: Health News